Axsome Therapeutics 株価情報 (NASDAQ: AXSM)

最新ニュース Axsome Therapeutics (NASDAQ:AXSM) 株価情報

Axsome Therapeutics

Axsome Therapeutics Inc is a clinical-stage biopharmaceutical company. It is engaged in developing novel therapies for the management of the central nervous system, or CNS, disorders for which there are limited treatment options. Its pipeline products include AXS-05, AXS-07, AXS-12, and AXS-14. It manages its business as one operating segment and reporting unit, which is the business of developing and delivering novel therapies for the management of CNS disorders.

Axsome Therapeutics Inc

Mizuho analyst Graig Suvannavejh maintains Axsome Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AXSM#NASDAQ">AXSM</a>) with a Outperform and raises the price target from $137 to $195.

News

Price Target

Analyst Ratings

AXSM

Mizuho Maintains Outperform on Axsome Therapeutics, Raises Price Target to $195

HC Wainwright &amp; Co. analyst Raghuram Selvaraju reiterates Axsome Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AXSM#NASDAQ">AXSM</a>) with a Buy and maintains $190 price target.

Reiteration

HC Wainwright & Co. Reiterates Buy on Axsome Therapeutics, Maintains $190 Price Target

<h3>Gainers</h3>
<ul>
<li>Biodexa Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BDRX#NASDAQ">BDRX</a>) stock moved upwards by 116.2% to $8.8 during Monday's pre-market session. The market value of their outstanding shares is at $5.8 million. </li>
<li>Ocean Biomedical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OCEA#NASDAQ">OCEA</a>) shares moved upwards by 70.57% to $0.23. The company's market cap stands at $7.9 million. </li>
<li>Solid Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SLDB#NASDAQ">SLDB</a>) shares rose 25.0% to $3.6. The market value of their outstanding shares is at $143.8 million. </li>
<li>IMAC Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BACK#NASDAQ">BACK</a>) stock moved upwards by 22.89% to $0.74. The market value of their outstanding shares is at $1.5 million. </li>
<li>Foghorn Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FHTX#NASDAQ">FHTX</a>) stock rose 17.05% to $5.56. The company's market cap stands at $309.2 million. </li>
<li>Axsome Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AXSM#NASDAQ">AXSM</a>) shares increased by 15.83% to $122.51. The market value of their outstanding shares is at $5.9 billion. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Pliant Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLRX#NASDAQ">PLRX</a>) shares decreased by 61.5% to $3.0 during Monday's pre-market session. The company's market cap stands at $182.5 million. </li>
<li>CytoMed Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GDTC#NASDAQ">GDTC</a>) stock fell 14.6% to $2.4. The company's market cap stands at $27.6 million. </li>
<li>ImmuCell (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ICCC#NASDAQ">ICCC</a>) stock decreased by 11.94% to $4.5. The company's market cap stands at $40.1 million. </li>
<li>Microbot Medical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MBOT#NASDAQ">MBOT</a>) shares declined by 10.99% to $2.27. The company's market cap stands at $63.6 million. </li>
<li>Cyclo Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CYTH#NASDAQ">CYTH</a>) stock fell 10.93% to $1.06. The market value of their outstanding shares is at $34.7 million. </li>
<li>Omega Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OMGA#NASDAQ">OMGA</a>) stock declined by 10.18% to $0.1. The company's market cap stands at $5.7 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Movers

BACK

BDRX

CYTH

FHTX

GDTC

ICCC

MBOT

OCEA

OMGA

PLRX

SLDB

12 Health Care Stocks Moving In Monday's Pre-Market Session

17 analysts have expressed a variety of opinions on Axsome Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AXSM#NASDAQ">AXSM</a>) over the past quarter, offering a diverse set of opinions from bullish to bearish.
The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">11</td>
<td align="right">6</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">5</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">2</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">3</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $149.24, along with a high estimate of $190.00 and a low estimate of $116.00. This upward trend is apparent, with the current average reflecting a 2.88% increase from the previous average price target of $145.06.
<img src="https://www.benzinga.com/files/images/story/2025/1739217639_0.png" alt="price target chart" />
<h2>Interpreting Analyst Ratings: A Closer Look</h2>
The standing of Axsome Therapeutics among financial experts becomes clear with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ami Fadia</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$133.00</td>
<td>$133.00</td>
</tr>
<tr>
<td>Graig Suvannavejh</td>
<td>Mizuho</td>
<td>Raises</td>
<td>Outperform</td>
<td>$137.00</td>
<td>$122.00</td>
</tr>
<tr>
<td>Joon Lee</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$190.00</td>
<td>$180.00</td>
</tr>
<tr>
<td>Brian Abrahams</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Outperform</td>
<td>$143.00</td>
<td>$139.00</td>
</tr>
<tr>
<td>Raghuram Selvaraju</td>
<td>HC Wainwright &amp; Co.</td>
<td>Raises</td>
<td>Buy</td>
<td>$190.00</td>
<td>$180.00</td>
</tr>
<tr>
<td>Brian Abrahams</td>
<td>RBC Capital</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$139.00</td>
<td>$139.00</td>
</tr>
<tr>
<td>Raghuram Selvaraju</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$180.00</td>
<td>$180.00</td>
</tr>
<tr>
<td>Ami Fadia</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$133.00</td>
<td>$133.00</td>
</tr>
<tr>
<td>Joon Lee</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$180.00</td>
<td>$150.00</td>
</tr>
<tr>
<td>Ami Fadia</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$133.00</td>
<td>$133.00</td>
</tr>
<tr>
<td>Graig Suvannavejh</td>
<td>Mizuho</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$122.00</td>
<td>$124.00</td>
</tr>
<tr>
<td>Ami Fadia</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$130.00</td>
<td>$130.00</td>
</tr>
<tr>
<td>Charles Duncan</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$121.00</td>
<td>$121.00</td>
</tr>
<tr>
<td>Raghuram Selvaraju</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$180.00</td>
<td>$180.00</td>
</tr>
<tr>
<td>Raghuram Selvaraju</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$180.00</td>
<td>$180.00</td>
</tr>
<tr>
<td>Joel Beatty</td>
<td>Baird</td>
<td>Raises</td>
<td>Outperform</td>
<td>$116.00</td>
<td>$112.00</td>
</tr>
<tr>
<td>Ami Fadia</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$130.00</td>
<td>$130.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Axsome Therapeutics. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Gaining insights, analysts provide qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Axsome Therapeutics compared to the broader market.</li>
<li>Price Targets: Analysts navigate through adjustments in price targets, providing estimates for Axsome Therapeutics's future value. Comparing current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
Analyzing these analyst evaluations alongside relevant financial metrics can provide a comprehensive view of Axsome Therapeutics's market position. Stay informed and make data-driven decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/AXSM/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Axsome Therapeutics analyst ratings.</a>
<h2>Get to Know Axsome Therapeutics Better</h2>
Axsome Therapeutics Inc is a clinical-stage biopharmaceutical company. It is engaged in developing novel therapies for the management of the central nervous system, or CNS, disorders for which there are limited treatment options. Its pipeline products include AXS-05, AXS-07, AXS-12, and AXS-14. It manages its business as one operating segment and reporting unit, which is the business of developing and delivering novel therapies for the management of CNS disorders.
<h3>Axsome Therapeutics's Economic Impact: An Analysis</h3>
Market Capitalization Analysis: Below industry benchmarks, the company's market capitalization reflects a smaller scale relative to peers. This could be attributed to factors such as growth expectations or operational capacity.
Revenue Growth: Axsome Therapeutics displayed positive results in 3 months. As of 30 September, 2024, the company achieved a solid revenue growth rate of approximately 81.27%. This indicates a notable increase in the company's top-line earnings. In comparison to its industry peers, the company stands out with a growth rate higher than the average among peers in the Health Care sector.
Net Margin: Axsome Therapeutics's net margin is below industry averages, indicating potential challenges in maintaining strong profitability. With a net margin of -61.67%, the company may face hurdles in effective cost management.
Return on Equity (ROE): Axsome Therapeutics's ROE falls below industry averages, indicating challenges in efficiently using equity capital. With an ROE of -66.0%, the company may face hurdles in generating optimal returns for shareholders.
Return on Assets (ROA): The company's ROA is below industry benchmarks, signaling potential difficulties in efficiently utilizing assets. With an ROA of -11.64%, the company may need to address challenges in generating satisfactory returns from its assets.
Debt Management: Axsome Therapeutics's debt-to-equity ratio is notably higher than the industry average. With a ratio of 2.07, the company relies more heavily on borrowed funds, indicating a higher level of financial risk.
<h2>The Significance of Analyst Ratings Explained</h2>
Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter. 
Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Investors who use analyst ratings should note that this specialized advice comes from humans and may be subject to error.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Beyond The Numbers: 17 Analysts Discuss Axsome Therapeutics Stock

On Monday, Axsome Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AXSM#NASDAQ">AXSM</a>) signed a settlement agreement with Teva Pharmaceuticals Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TEVA#NYSE">TEVA</a>).
The settlement resolves all patent litigation related to Axsome&#8217;s Auvelity (dextromethorphan HBr – <a target="_blank" href="https://www.benzinga.com/pressreleases/25/02/g43588347/axsome-therapeutics-announces-settlement-agreement-resolving-auvelity-dextromethorphan-hbr-bupropi" rel="noreferrer noopener">bupropion HCl) product</a>.
Auvelity is approved in the U.S. for major depressive disorder.
The litigation resulted from Teva submitting an Abbreviated New Drug Application to the U.S. Food and Drug Administration (FDA) seeking approval to market a generic version of Auvelity in the U.S. before the expiration of applicable Axsome patents.
Also Read: <a target="_blank" href="https://www.benzinga.com/24/12/42739705/axsome-reveals-data-from-alzheimers-studies-analyst-sees-hope-despite-mixed-trial-results" rel="noreferrer noopener">Axsome Reveals Data From Alzheimer&#8217;s Studies, Analyst Sees Hope Despite Mixed Trial Results</a>
Under the terms of the settlement agreement, Axsome will grant Teva a license to sell its generic version of Auvelity beginning on or after March 31, 2039, if pediatric exclusivity is granted for Auvelity, or on or after September 30, 2038, if no pediatric exclusivity is granted.
The parties will terminate all ongoing litigation between Axsome and Teva regarding Auvelity patents pending in the U.S. District Court for the District of New Jersey.
In January, Axsome Therapeutics reported preliminary Auvelity net product sales are expected to be approximately $92.6 million and $291.4 million for the fourth quarter and <a target="_blank" href="https://www.benzinga.com/pressreleases/25/01/g42940823/axsome-therapeutics-provides-preliminary-fourth-quarter-and-full-year-2024-net-revenue" rel="noreferrer noopener">full year of 2024, respectively</a>.
Recently, the FDA approved Axsome Therapeutics&#8217; Symbravo&nbsp;(meloxicam and rizatriptan) for the acute treatment of migraine with or <a target="_blank" href="https://www.benzinga.com/pressreleases/25/01/g43351848/axsome-therapeutics-announces-fda-approval-of-symbravo-meloxicam-and-rizatriptan-for-the-acute-tre" rel="noreferrer noopener">without aura in adults</a>.
&#8220;Axsome is our top pick for 2025,&#8221; William Blair writes. Analyst Myles Minter reiterates the Outperform rating based on favorable litigation settlement and clarity on Auvelity&#8217;s generic launch timing.
&#8220;We also remain impressed with the Auvelity launch, which showed 15% growth in revenue over the prior quarter and is annualizing about $370 million after two years of launch,&#8221; William Blair adds.
Axsome now has three commercial products with the approval of Symbravo for migraines. While investors are mainly watching Auvelity's rollout for depression and its potential use in Alzheimer's-related agitation, analyst Minter writes Symbravo's potential in treating acute migraines is being overlooked.
William Blair also views Axsome as a takeout candidate with Johnson &amp; Johnson buying Intra-Cellular Therapies Inc. <a target="_blank" href="https://www.benzinga.com/general/biotech/25/01/42948170/like-bristol-myers-squibb-and-abbvie-johnson-johnson-seeks-to-bolster-neuropsychiatric-portfolio-with-15-billion-deal" rel="noreferrer noopener">for $14.6 billion</a>.
Needham analyst Ami Fadia reiterates Axsome Therapeutics with a Buy and maintains a <a target="_blank" href="https://www.benzinga.com/quote/AXSM/analyst-ratings" rel="noreferrer noopener">$133 price target</a>.
Price Action: AXSM stock is up 24.6% at $131.77 at last check Monday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/02/43597173/whats-going-on-with-bristol-myers-squibb-stock-on-monday" target="_blank" rel="noreferrer noopener">What&#8217;s Going On With Bristol Myers Squibb Stock On Monday?</a></li>
</ul>
Photo: Courtesy of Ulf Wittrock via Shutterstock.

Analyst Color

Biotech

Equities

Health Care

Legal

Trading Ideas

General

TEVA

Axsome Therapeutics Resolves Generic Patent Litigation With Teva Over Depression Drug, Analyst Maintains Axsome As 'Top Pick For 2025'

Needham analyst Ami Fadia reiterates Axsome Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AXSM#NASDAQ">AXSM</a>) with a Buy and maintains $133 price target.

Needham Reiterates Buy on Axsome Therapeutics, Maintains $133 Price Target

U.S. stocks were higher, with the Nasdaq Composite gaining around 200 points on Monday.
Shares of Rockwell Automation, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ROK#NYSE">ROK</a>) rose sharply during Monday's session after the company reported <a href="https://in.benzinga.com/25/02/43596322/rockwell-automation-q1-results-defie-sales-decline-with-higher-margins-and-strong-cash-flow">first-quarter earnings above estimates.</a>
Rockwell Automation said sales fell 8.4% year over year and slid 7.6% organically to $1.881 billion, in line with the consensus of $1.881 billion. Total ARR grew 11%. Adjusted EPS was $1.83 (-10% YoY), above the analyst consensus of $1.59.
Rockwell Automation shares jumped 10.5% to $296.78 on Monday.
Here are some other big stocks recording gains in today's session.
<ul>
<li>SpringWorks Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SWTX#NASDAQ">SWTX</a>) shares jumped 30.2% to $52.45 after announcing Merck KGaA is in advanced discussions to acquire the company.</li>
<li>monday.com Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MNDY#NASDAQ">MNDY</a>) gained 28.8% to $332.78 after the company reported better-than-expected fourth-quarter financial results and first-quarter revenue outlook.</li>
<li>PowerFleet, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AIOT#NASDAQ">AIOT</a>) rose 24.2% to $7.39 after the company reported better-than-expected Q3 sales results and raised its FY25 sales and adjusted EBITDA guidance.</li>
<li>Satellogic Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SATL#NASDAQ">SATL</a>) gained 22.4% to $4.5200.</li>
<li>AST SpaceMobile, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ASTS#NASDAQ">ASTS</a>) climbed 18.8% to $31.50.</li>
<li>Axsome Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AXSM#NASDAQ">AXSM</a>) rose 18.8% to $125.70 after the company reached a settlement agreement with Teva Pharmaceuticals resolving all patent litigation related to its Auvelity product.</li>
<li>Mobileye Global Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MBLY#NASDAQ">MBLY</a>) gained 16.2% to $18.67 after B of A Securities upgraded the stock from Underperform to Neutral and raised its price target from $12 to $19.</li>
<li>Century Aluminum Company (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CENX#NASDAQ">CENX</a>) rose 15% to $21.50. Shares of steel and aluminum stocks traded higher after reports President Trump plans additional 25% tariffs on steel and aluminum.</li>
<li>Cleveland-Cliffs Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CLF#NYSE">CLF</a>) gained 11.6% to $11.19. Shares of steel and aluminum stocks traded higher after reports President Trump plans additional 25% tariffs on steel and aluminum.</li>
<li>Insperity, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NSP#NYSE">NSP</a>) rose 11.4% to $77.51 after the company reported better-than-expected fourth-quarter financial results.</li>
<li>Light &amp; Wonder, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LNW#NASDAQ">LNW</a>) rose 11% to $97.64.</li>
<li>Roku, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ROKU#NASDAQ">ROKU</a>) surged 6.7% to $90.85.</li>
<li>BP p.l.c. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BP#NYSE">BP</a>) rose 6.3% to $34.32 after a report from The Wall Street Journal said Elliott Management has built a stake in the company and will push for changes.</li>
<li>Alibaba Group Holding Limited (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BABA#NYSE">BABA</a>) gained 6.1% to $109.84 after President Trump reportedly postponed tariffs on packages under $800 from China.</li>
<li>United States Steel Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/X#NYSE">X</a>) rose 5.5% to $38.99.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/25/02/43593480/wall-streets-most-accurate-analysts-give-their-take-on-3-real-estate-stocks-with-over-6-dividend-yields-2">Wall Street&#8217;s Most Accurate Analysts Give Their Take On 3 Real Estate Stocks With Over 6% Dividend Yields</a></li>
</ul>

Earnings

Markets

AIOT

ASTS

BABA

CENX

MBLY

MNDY

ROKU

SATL

SWTX

Rockwell Automation Posts Upbeat Earnings, Joins Insperity, BP, Alibaba And Other Big Stocks Moving Higher On Monday

WIIM

Axsome Therapeutics shares are trading higher after the company reached a settlement agreement with Teva Pharmaceuticals resolving all patent litigation related to its Auvelity product.

<ul>
<li>The litigation resulted from submission by Teva of an Abbreviated New Drug Application to the FDA seeking approval to market a generic version of AUVELITY in the United States prior to the expiration of applicable Axsome patents.</li>
<li>Under the terms of the settlement agreement, Axsome will grant Teva a license to sell its generic version of AUVELITY beginning on or after March 31, 2039, if pediatric exclusivity is granted for AUVELITY, or on or after September 30, 2038, if no pediatric exclusivity is granted, subject to FDA approval and conditions and exceptions customary for agreements of this type. In accordance with the agreement, the parties will terminate all ongoing litigation between Axsome and Teva regarding AUVELITY patents pending in the U.S. District Court for the District of New Jersey.</li>
</ul>

Axsome Therapeutics Entered Into A Settlement Agreement With Teva Pharmaceuticals Resolving All Patent Litigation Related To Axsome's Auvelity (Dextromethorphan HBR – Bupropion HCL) Product

Mizuho analyst Graig Suvannavejh maintains Axsome Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AXSM#NASDAQ">AXSM</a>) with a Outperform and raises the price target from $122 to $137.

Mizuho Maintains Outperform on Axsome Therapeutics, Raises Price Target to $137

Truist Securities analyst Joon Lee maintains Axsome Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AXSM#NASDAQ">AXSM</a>) with a Buy and raises the price target from $180 to $190.

Truist Securities Maintains Buy on Axsome Therapeutics, Raises Price Target to $190

RBC Capital analyst Brian Abrahams maintains Axsome Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AXSM#NASDAQ">AXSM</a>) with a Outperform and raises the price target from $139 to $143.

RBC Capital Maintains Outperform on Axsome Therapeutics, Raises Price Target to $143

HC Wainwright &amp; Co. analyst Raghuram Selvaraju maintains Axsome Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AXSM#NASDAQ">AXSM</a>) with a Buy and raises the price target from $180 to $190.

HC Wainwright & Co. Maintains Buy on Axsome Therapeutics, Raises Price Target to $190

A single oral dose of SYMBRAVO provided rapid migraine pain freedom and return to normal functioning within 2 hours, and sustained efficacy through 24 and 48 hours
85% and 77% of patients treated with a single dose of SYMBRAVO did not require migraine rescue medication within 24 hours in two Phase 3 studies
SYMBRAVO demonstrated superior efficacy across a broad range of migraine severity (mild, moderate, and severe), and in head-to-head evaluation
SYMBRAVO incorporates Axsome's rapid absorption technology and mechanisms that target multiple migraine attack pathways
Company to host conference call and webcast Friday, January 31, at 8:00 AM Eastern
NEW YORK, Jan. 30, 2025 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AXSM#NASDAQ">AXSM</a>), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today announced that the U.S. Food and Drug Administration (FDA) has approved SYMBRAVO&#xAE; (meloxicam and rizatriptan) for the acute treatment of migraine with or without aura in adults.1 SYMBRAVO represents a novel multi-mechanistic approach to treating migraine that targets multiple pathways underlying a migraine attack. SYMBRAVO can rapidly eliminate migraine pain and return patients to normal functioning, with efficacy sustained through 24 and 48 hours in some patients after a single dose. The efficacy of SYMBRAVO was demonstrated across a broad range of settings including at the earliest onset of migraine when the pain was mild, in patients with moderate and severe migraine pain, and in those with a history of various responses to prior acute treatments. The Company expects SYMBRAVO to be commercially available in the U.S. in approximately four months.

Axsome Therapeutics Announces FDA Approval Of SYMBRAVO For The Acute Treatment Of Migraine With Or Without Aura In Adults; 85% And 77% Of Patients Treated With A Single Dose Of SYMBRAVO Did Not Require Migraine Rescue Medication Within 24 Hours In Two Phase 3 Studies

RBC Capital analyst Brian Abrahams maintains Axsome Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AXSM#NASDAQ">AXSM</a>) with a Outperform and maintains $139 price target.

RBC Capital Maintains Outperform on Axsome Therapeutics, Maintains $139 Price Target

Axsome Therapeutics shares are trading higher. HC Wainwright & Co. reiterated a Buy rating on the stock.

Ratings for Axsome Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AXSM#NASDAQ">AXSM</a>) were provided by 12 analysts in the past three months, showcasing a mix of bullish and bearish perspectives.
The following table summarizes their recent ratings, shedding light on the changing sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">9</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">4</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Insights from analysts' 12-month price targets are revealed, presenting an average target of $144.58, a high estimate of $180.00, and a low estimate of $116.00. This current average has increased by 1.87% from the previous average price target of $141.92. 
<img src="https://www.benzinga.com/files/images/story/2025/1737464475_0.png" alt="price target chart" />
<h2>Breaking Down Analyst Ratings: A Detailed Examination</h2>
In examining recent analyst actions, we gain insights into how financial experts perceive Axsome Therapeutics. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Raghuram Selvaraju</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$180.00</td>
<td>$180.00</td>
</tr>
<tr>
<td>Ami Fadia</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$133.00</td>
<td>$133.00</td>
</tr>
<tr>
<td>Joon Lee</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$180.00</td>
<td>$150.00</td>
</tr>
<tr>
<td>Ami Fadia</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$133.00</td>
<td>$133.00</td>
</tr>
<tr>
<td>Graig Suvannavejh</td>
<td>Mizuho</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$122.00</td>
<td>$124.00</td>
</tr>
<tr>
<td>Ami Fadia</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$130.00</td>
<td>$130.00</td>
</tr>
<tr>
<td>Charles Duncan</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$121.00</td>
<td>$121.00</td>
</tr>
<tr>
<td>Raghuram Selvaraju</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$180.00</td>
<td>$180.00</td>
</tr>
<tr>
<td>Raghuram Selvaraju</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$180.00</td>
<td>$180.00</td>
</tr>
<tr>
<td>Joel Beatty</td>
<td>Baird</td>
<td>Raises</td>
<td>Outperform</td>
<td>$116.00</td>
<td>$112.00</td>
</tr>
<tr>
<td>Ami Fadia</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$130.00</td>
<td>$130.00</td>
</tr>
<tr>
<td>Ami Fadia</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$130.00</td>
<td>$130.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Axsome Therapeutics. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Gaining insights, analysts provide qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Axsome Therapeutics compared to the broader market.</li>
<li>Price Targets: Analysts navigate through adjustments in price targets, providing estimates for Axsome Therapeutics's future value. Comparing current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
For valuable insights into Axsome Therapeutics's market performance, consider these analyst evaluations alongside crucial financial indicators. Stay well-informed and make prudent decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/AXSM/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Axsome Therapeutics analyst ratings.</a>
<h2>All You Need to Know About Axsome Therapeutics</h2>
Axsome Therapeutics Inc is a clinical-stage biopharmaceutical company. It is engaged in developing novel therapies for the management of the central nervous system, or CNS, disorders for which there are limited treatment options. Its pipeline products include AXS-05, AXS-07, AXS-12, and AXS-14. It manages its business as one operating segment and reporting unit, which is the business of developing and delivering novel therapies for the management of CNS disorders.
<h3>Understanding the Numbers: Axsome Therapeutics's Finances</h3>
Market Capitalization: Indicating a reduced size compared to industry averages, the company's market capitalization poses unique challenges.
Revenue Growth: Axsome Therapeutics's remarkable performance in 3 months is evident. As of 30 September, 2024, the company achieved an impressive revenue growth rate of 81.27%. This signifies a substantial increase in the company's top-line earnings. As compared to competitors, the company surpassed expectations with a growth rate higher than the average among peers in the Health Care sector.
Net Margin: Axsome Therapeutics's net margin is below industry standards, pointing towards difficulties in achieving strong profitability. With a net margin of -61.67%, the company may encounter challenges in effective cost control.
Return on Equity (ROE): Axsome Therapeutics's ROE lags behind industry averages, suggesting challenges in maximizing returns on equity capital. With an ROE of -66.0%, the company may face hurdles in achieving optimal financial performance.
Return on Assets (ROA): Axsome Therapeutics's ROA falls below industry averages, indicating challenges in efficiently utilizing assets. With an ROA of -11.64%, the company may face hurdles in generating optimal returns from its assets.
Debt Management: Axsome Therapeutics's debt-to-equity ratio is notably higher than the industry average. With a ratio of 2.07, the company relies more heavily on borrowed funds, indicating a higher level of financial risk.
<h2>What Are Analyst Ratings?</h2>
Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.
Beyond their standard evaluations, some analysts contribute predictions for metrics like growth estimates, earnings, and revenue, furnishing investors with additional guidance. Users of analyst ratings should be mindful that this specialized advice is shaped by human perspectives and may be subject to variability.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

12 Analysts Have This To Say About Axsome Therapeutics

HC Wainwright &amp; Co. analyst Raghuram Selvaraju reiterates Axsome Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AXSM#NASDAQ">AXSM</a>) with a Buy and maintains $180 price target.

HC Wainwright & Co. Reiterates Buy on Axsome Therapeutics, Maintains $180 Price Target

Axsome Therapeutics shares are trading higher after the company reported preliminary Q4 and FY2024 net product revenue. Additionally, Truist Securities raised its price target on the stock from $150 to $180 while maintaining a Buy rating.

Axsome settles Auvelity patent litigation with Teva

Shares in biopharmaceutical group Axsome Therapeutics ($AXSM) surged 23% today after it said it had settled a legal dispute with peer Teva Pharmace...

Shares in Biopharma Firm Axsome Surge Over 20% After Settling Teva Patent Dispute

Analyst Marc Goodman from Leerink Partners maintained a Buy rating on Axsome Therapeutics (AXSM – Research Report) and increased the price target t...

Analyst Upgrades Axsome to Buy Amid Key Settlement with Teva and Raised Price Target

Leerink raised the firm's price target on Axsome Therapeutics (AXSM) to $150 from $110 and keeps an Outperform rating on the shares. The settlement...

Axsome Therapeutics price target raised to $150 from $110 at Leerink

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Incyte (INCY – Research Report), Axsome Therapeuti...

Analysts Conflicted on These Healthcare Names: Incyte (INCY), Axsome Therapeutics (AXSM) and Vertex Pharmaceuticals (VRTX)

Deutsche Bank analyst David Hoang initiated coverage of Axsome Therapeutics (AXSM) with a Buy rating and $176 price target Published first on TheFl...

Axsome Therapeutics initiated with a Buy at Deutsche Bank

There's a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Day One Biopharmaceuticals (DAWN – Research Report),...

Analysts Are Bullish on These Healthcare Stocks: Day One Biopharmaceuticals (DAWN), Health Catalyst (HCAT)

Mizuho raised the firm's price target on Axsome Therapeutics (AXSM) to $195 from $137 and keeps an Outperform rating on the shares following the pa...

Axsome Therapeutics price target raised to $195 from $137 at Mizuho

TD Cowen raised the firm's price target on Axsome Therapeutics (AXSM) to $190 from $155 and keeps a Buy rating on the shares. The company announced...

TD ups Axsome target, sees takeout speculation on patent settlement

BofA analyst Jason Gerberry raised the firm's price target on Axsome Therapeutics (AXSM) to $167 from $143 and keeps a Buy rating on the shares aft...

Axsome Therapeutics price target raised to $167 from $143 at BofA

DAWN

HCAT

INCY

VRTX

Screenshot 2024-07-10 at 9.08.28 PM

TNXP

A Redux Of The Lyrica-Cymbalta Fibromyalgia War Of The 2010s May Look More Like David Vs. Goliath

Screenshot 2024-02-24 at 12.03.42 AM

ABBV

New Drug Study Shows Improving Sleep Quality Can Relieve Fibromyalgia Pain

Press Releases

Axsome Therapeutics Presents Data from Multiple Programs Spanning Its Innovative Neuroscience Portfolio at Psych Congress 2024

Axsome Therapeutics Presents Data from Its Leading Neuroscience Pipeline at NEI Congress 2024

Axsome Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update

Axsome Therapeutics Announces AXS-12 Achieves Primary Endpoint in ENCORE Long-Term Phase 3 Trial in Narcolepsy

Axsome Therapeutics Announces Successful Completion and Results of Phase 3 Clinical Program of AXS-05 in Alzheimer's Disease Agitation

Axsome Therapeutics Provides Preliminary Fourth Quarter and Full Year 2024 Net Revenue

Axsome Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results on February 18

Axsome Therapeutics Announces FDA Approval of SYMBRAVO® (meloxicam and rizatriptan) for the Acute Treatment of Migraine with or without Aura in Adults

Axsome Therapeutics Hosts SYMBRAVO® FDA Approval Virtual Investor Event with Expert Thought Leader

Axsome Therapeutics Announces Settlement Agreement Resolving AUVELITY® (dextromethorphan HBr – bupropion HCl) Patent Litigation

AstraZeneca PLC - American Depositary Shares

AstraZeneca

Bristol-Myers Squibb Company Common Stock

Bristol-Myers Squibb

Corcept Therapeutics Incorporated - Common Stock

Corcept Therapeutics

Elanco Animal Health Incorporated Common Stock

Elanco Animal Health

Edgewise Therapeutics, Inc. - Common Stock

Edgewise Therapeutics

GSK plc American Depositary Shares (Each representing two Ordinary Shares)

Haleon plc American Depositary Shares (Each representing two Ordinary Shares)

Haleon

Intra-Cellular Therapies Inc. - Common Stock

Intra-Cellular Therapies

Jazz Pharmaceuticals plc - Ordinary Shares

Jazz Pharmaceuticals

Johnson & Johnson

Eli Lilly

Merck & Co

Novo Nordisk

Novartis

Organon

Prestige Consumer Healthcare Inc. Common Stock

Prestige Consumer

Pfizer

Dr. Reddy's Laboratories Ltd Common Stock

Dr Reddy's Laboratories

Royalty Pharma plc - Class A Ordinary Shares

Royalty Pharma

Sanofi

Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)

Comments

Axsome Therapeutics

ニュース

最新ニュース Axsome Therapeutics (NASDAQ:AXSM) 株価情報

こんな人も見ています

ニュース

パートナーシップ

ベンジンガ・グローバル